425 related articles for article (PubMed ID: 29386072)
61. Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma.
Qin Q; Nan X; Miller T; Fisher R; Teh B; Pandita S; Farach AM; Pingali SR; Pandita RK; Butler EB; Pandita TK; Iyer SP
Radiat Res; 2018 Sep; 190(3):322-329. PubMed ID: 29949442
[TBL] [Abstract][Full Text] [Related]
62. Encouraging prospects with sugemalimab in relapsed or refractory extranodal natural killer/T-cell lymphoma.
Shi W; Lu T; Xu-Monette Y; Young KH
Chin Clin Oncol; 2024 Feb; 13(1):17. PubMed ID: 38073311
[No Abstract] [Full Text] [Related]
63. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Daud AI; Wolchok JD; Robert C; Hwu WJ; Weber JS; Ribas A; Hodi FS; Joshua AM; Kefford R; Hersey P; Joseph R; Gangadhar TC; Dronca R; Patnaik A; Zarour H; Roach C; Toland G; Lunceford JK; Li XN; Emancipator K; Dolled-Filhart M; Kang SP; Ebbinghaus S; Hamid O
J Clin Oncol; 2016 Dec; 34(34):4102-4109. PubMed ID: 27863197
[TBL] [Abstract][Full Text] [Related]
64. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
Yamaguchi M; Kwong YL; Kim WS; Maeda Y; Hashimoto C; Suh C; Izutsu K; Ishida F; Isobe Y; Sueoka E; Suzumiya J; Kodama T; Kimura H; Hyo R; Nakamura S; Oshimi K; Suzuki R
J Clin Oncol; 2011 Nov; 29(33):4410-6. PubMed ID: 21990393
[TBL] [Abstract][Full Text] [Related]
65. Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports.
Rivera-Francia VM; Failoc-Rojas VE; Villacorta-Carranza R; Leon Garrido-Lecca A; Calle-Villavicencio A; Torres-Mera A; Valladares-Garido MJ; Huerta-Collado Y; Motta-Guerrero R; Casanova Marquez L
Leuk Lymphoma; 2024 Jan; 65(1):37-47. PubMed ID: 37794819
[TBL] [Abstract][Full Text] [Related]
66. Pembrolizumab as second-line treatment for urothelial cancer.
Mitchell F
Lancet Oncol; 2017 Apr; 18(4):e197. PubMed ID: 28238595
[No Abstract] [Full Text] [Related]
67. L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type.
Yong W; Zheng W; Zhu J; Zhang Y; Wang X; Xie Y; Lin N; Xu B; Lu A; Li J
Ann Hematol; 2009 Jul; 88(7):647-52. PubMed ID: 19107482
[TBL] [Abstract][Full Text] [Related]
68. Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: high efficacy with minimal toxicity.
Chan TS; Luk TH; Lau JS; Khong PL; Kwong YL
Ann Hematol; 2017 Apr; 96(4):647-651. PubMed ID: 28138786
[TBL] [Abstract][Full Text] [Related]
69. Efficacy and tolerance of pegaspargase-based chemotherapy in patients with nasal-type extranodal NK/T-cell lymphoma: a pilot study.
Wen JY; Li M; Li X; Chen J; Lin Q; Ma XK; Dong M; Wei L; Chen ZH; Wu XY
Asian Pac J Cancer Prev; 2014; 15(15):6275-81. PubMed ID: 25124611
[TBL] [Abstract][Full Text] [Related]
70. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Bellmunt J; de Wit R; Vaughn DJ; Fradet Y; Lee JL; Fong L; Vogelzang NJ; Climent MA; Petrylak DP; Choueiri TK; Necchi A; Gerritsen W; Gurney H; Quinn DI; Culine S; Sternberg CN; Mai Y; Poehlein CH; Perini RF; Bajorin DF;
N Engl J Med; 2017 Mar; 376(11):1015-1026. PubMed ID: 28212060
[TBL] [Abstract][Full Text] [Related]
71. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
[TBL] [Abstract][Full Text] [Related]
72. Successful treatment by pembrolizumab in a patient with end-stage renal disease with advanced non-small cell lung cancer and high PD-L1 expression.
Ishizuka S; Sakata S; Yoshida C; Takaki A; Saeki S; Nakamura K; Fujii K
Respir Investig; 2018 Jul; 56(4):361-364. PubMed ID: 29764752
[TBL] [Abstract][Full Text] [Related]
73. Pembrolizumab for Recurrent Conjunctival Melanoma.
Kini A; Fu R; Compton C; Miller DM; Ramasubramanian A
JAMA Ophthalmol; 2017 Aug; 135(8):891-892. PubMed ID: 28715523
[No Abstract] [Full Text] [Related]
74. Clinical disparity and favorable prognoses for patients with Waldeyer ring extranodal nasal-type NK/T-cell lymphoma and diffuse large B-cell lymphoma.
Wu RY; Li YX; Wang WH; Jin J; Wang SL; Liu YP; Song YW; Fang H; Ren H; Liu QF; Wang ZY; Qi SN; Lu NN; Chen B; Zhang XM; Zhou LQ; Liu XF; Yu ZH
Am J Clin Oncol; 2014 Feb; 37(1):41-6. PubMed ID: 22992625
[TBL] [Abstract][Full Text] [Related]
75. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
Lesokhin AM; Ansell SM; Armand P; Scott EC; Halwani A; Gutierrez M; Millenson MM; Cohen AD; Schuster SJ; Lebovic D; Dhodapkar M; Avigan D; Chapuy B; Ligon AH; Freeman GJ; Rodig SJ; Cattry D; Zhu L; Grosso JF; Bradley Garelik MB; Shipp MA; Borrello I; Timmerman J
J Clin Oncol; 2016 Aug; 34(23):2698-704. PubMed ID: 27269947
[TBL] [Abstract][Full Text] [Related]
76. PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy.
Nishino M; Ramaiya NH; Hatabu H; Hodi FS; Armand PF
Br J Haematol; 2018 Mar; 180(5):752-755. PubMed ID: 27861725
[No Abstract] [Full Text] [Related]
77. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
[TBL] [Abstract][Full Text] [Related]
78. Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4).
Tao R; Fan L; Song Y; Hu Y; Zhang W; Wang Y; Xu W; Li J
Signal Transduct Target Ther; 2021 Oct; 6(1):365. PubMed ID: 34702811
[TBL] [Abstract][Full Text] [Related]
79. PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.
Peters S; Kerr KM; Stahel R
Cancer Treat Rev; 2018 Jan; 62():39-49. PubMed ID: 29156447
[TBL] [Abstract][Full Text] [Related]
80. Immunophenotypic and clinical differences between the nasal and extranasal subtypes of upper aerodigestive tract natural killer/T-cell lymphoma.
Liu QF; Wang WH; Wang SL; Liu YP; Huang WT; Lu N; Zhou LQ; Ouyang H; Jin J; Li YX
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):806-13. PubMed ID: 24495590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]